Popular on EntSun
- Onshore to Generate 68% of the Revenue in Oil and Gas Management Software Management Market 130
- Injured Noted Ballet Dancer On The Comeback Trail
- Relocate Easily With Faridabad Moving Company
- Cora Alpha Elysium City Update
- Get in Touch with Alanic Clothing for Ordering Exclusive Sports Clothing
- Former CNN host Keturah King nabs her an apron on the 10th season of MasterChef
- Addepto Launches Global R&D Center for Development of Breakthrough AI Solutions
- Johnny Cash Tribute Show Comes To Hartford
- Minority Reportz Presents Desi Girls Night Out Comedy Show & After Party
- AutoQuotes Announces Appointment Of New CEO
Similar on EntSun
- Topaz Information Solutions adds key partner True Mobile Health to enhance care to provider organizations
- San Diego Luxury Brokerage Willis Allen Real Estate Launches New Tech Stack
- PINC recognized as a standout exhibitor during the largest ProMat expo in the 34-year history
- Formerly Homeless Latino Software Engineer Proves Talent on "Whiteboard Challenge" Show
- Join Our Personalization App Party and Make Your Phone Look UNIQUE
- Telaeris Announces New Integration with Kantech Entrapass Access Control
- Extraordinarily High Wages For Cannabis Workers In SVG From Foreign Investor – Cannavais
- Triage Partners Licenses WipIT™ SaaS to Global Logistics Company
- Blackhawk Plastic Surgery Welcomes Expert Plastic Surgeon, Timothy Rankin MD
- Aura Alliance Partners with InfoPlus
Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany
EntSun News/10776330
The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer
MUNICH, Germany - May 13, 2019 - EntSun -- May 13 2019, Garching n. Munich, Germany– OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that the interregional professional association for nuclear medicine in Hanau now offers the Rhenium-SCT ® (SCT= Skin Cancer Therapy) as the first treatment center in Germany.
With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods which are state-of the art in science and technology.
"Offering NMSC skin cancer patients a highly efficient, painless, innovative therapy with excellent aesthetic results was the driving reason to establish this treatment method in our clinic," says Dr. med. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.
"We are delighted that our innovative skin cancer therapy Rhenium-SCT® is now being offered by the Nuclear Medicine in Hanau and we are looking forward to this collaboration", states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "For us, this is an important step to offer the treatment method in addition to Italy, South Africa and Australia now also in Germany. In order to provide our treatment to as many skin cancer patients as possible, it is of course our goal to offer the availability of the therapy nationwide in Germany in the future."
More on EntSun News
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In Germany the number of newly diagnosed patients is about 200,000 annually and it is assumed that this number increases within the next years. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.
If interested, patients and doctors can either contact the interregional professional association for nuclear medicine in Hanau directly or OncoBeta® GmbH.
Contact details:
Überörtliche Berufsausübungsgemeinschaft Nuklearmedizin
Nußallee 7 F
63450 Hanau
Phone.: +49 (0)6181/ 427 886-0
Email: heller-hautkrebs@nuk-hu.de
OncoBeta® GmbH
Phone: +49 (0)89/ 548 4224-0
Email: info@oncobeta.com
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
More on EntSun News
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.
Find out more about the Rhenium-SCT® at https://www.oncobeta.com/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no
obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
END
With approximately 50.000 outpatient examinations annually, the interregional professional association for nuclear medicine Hanau is one of the biggest nuclear medicine service providers in Hesse. The offered services include a variety of different modern treatment and diagnostic methods which are state-of the art in science and technology.
"Offering NMSC skin cancer patients a highly efficient, painless, innovative therapy with excellent aesthetic results was the driving reason to establish this treatment method in our clinic," says Dr. med. Lutz-Hendrik Holle, Medical Director of Nuclear Medicine in Hanau.
"We are delighted that our innovative skin cancer therapy Rhenium-SCT® is now being offered by the Nuclear Medicine in Hanau and we are looking forward to this collaboration", states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "For us, this is an important step to offer the treatment method in addition to Italy, South Africa and Australia now also in Germany. In order to provide our treatment to as many skin cancer patients as possible, it is of course our goal to offer the availability of the therapy nationwide in Germany in the future."
More on EntSun News
- Millennials are Ruining the World? an Xennial perspective bridges the gap between Generations X & Y
- PINC recognized as a standout exhibitor during the largest ProMat expo in the 34-year history
- Michael Jordan, author of The Company of Demons, News and Events
- Benefits of gym memberships near me
- Endovenous laser therapy (evlt)
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. In Germany the number of newly diagnosed patients is about 200,000 annually and it is assumed that this number increases within the next years. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.
If interested, patients and doctors can either contact the interregional professional association for nuclear medicine in Hanau directly or OncoBeta® GmbH.
Contact details:
Überörtliche Berufsausübungsgemeinschaft Nuklearmedizin
Nußallee 7 F
63450 Hanau
Phone.: +49 (0)6181/ 427 886-0
Email: heller-hautkrebs@nuk-hu.de
OncoBeta® GmbH
Phone: +49 (0)89/ 548 4224-0
Email: info@oncobeta.com
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
More on EntSun News
- Doc Cotton Launches Marketplace for Sustainable Fashion
- Best Training in Bangalore|Embedded Systems Course in Bangalore | ETech Prowess
- Get a gorgeous hairdo with lace wigs
- Best Quality Hair Extensions
- ILines Now Offers High-End Residential and Commercial Architecture Services
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.
Find out more about the Rhenium-SCT® at https://www.oncobeta.com/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no
obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
END
Source: OncoBeta GmbH
Filed Under: Beauty, Technology
0 Comments
Latest on EntSun News
- Tuesday Night Comics at North Coast Rep
- Ideation at North Coast Repertory Theatre
- Comic-Con Best Documentary Winner About Artist Who Inspired US Space Program Heads for SoCal Launch
- Revitalization of the Fashion Business Concept Communicates a Powerful Force
- IFLM Special Shareholders Meeting - Early Notice
- Diamond Bridal Gallery Celebrates Success Offering Custom Made Wedding Dresses
- Extraordinarily High Wages For Cannabis Workers In SVG From Foreign Investor – Cannavais
- Shell Point's 2019 Summer Concert Series welcomes Aibou Duo July 10
- Triage Partners Licenses WipIT™ SaaS to Global Logistics Company
- Miami-Dade County Youth Fair & Exposition selects Eduardo Cora as president and CEO
- Blackhawk Plastic Surgery Welcomes Expert Plastic Surgeon, Timothy Rankin MD
- Afro Soundz Radio Is Now On The Air
- 10TH ANNUAL SOHO International Film Festival - Thursday June 20th through June 27th
- Introducing the 2019 Class of the Cultural Vistas Fellowship
- New Semi-Pro Football League Announces Team Names and Logos
- One Park Financial Honored with "Company of the Year" Stevie® Award
- New Music Series Beatbites Kicks Off Season 3; Social Media Changing The Way We Stream Music
- Star Launches New Tool for Branding Made Simple
- National ATM Council Announces Debbi Haacke as Vice-Chair of NAC Governmental Affairs Committee
- The "Do's" & "Don'ts" One Should Not Forget in a Long-Distance Relationship